{
    "clinical_study": {
        "@rank": "14925", 
        "arm_group": {
            "arm_group_label": "Abiraterone acetate", 
            "description": "All patients will be receiving abiraterone acetate as per standard of care"
        }, 
        "brief_summary": {
            "textblock": "Adrenal androgens are serum biomarkers of interest that may help guide abiraterone acetate\n      treatment, particularly at the time of progression. Biomarkers may also help identify\n      pathways to resistance of abiraterone acetate treatment. The most practical way of\n      approaching this question is to explore surrogate biomarkers of prostate cancer including\n      quantification of pharmacodynamic endocrine biomarkers."
        }, 
        "brief_title": "A Correlative Study of Biomarkers of Resistance in Patients With Castrate Resistant Prostate Cancer Treated With Abiraterone", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Prostate Cancer (Adenocarcinoma)", 
        "condition_browse": {
            "mesh_term": [
                "Adenocarcinoma", 
                "Prostatic Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "Goals of this study include:\n\n        -  Explore which circulating endocrine markers or endocrine related markers have the best\n           potential to predict clinical response to abiraterone acetate in CRPC patients\n\n        -  Explore the utility of microRNA, circulating DNA and exosome analyses in complementing\n           the previous objective"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Signed written informed consent. Before any study procedures are performed, subjects\n             (or their legally acceptable representatives) will have the details of the study\n             described to them, and they will be given a written informed consent document to\n             read. If subjects consent to participate in the study, they will indicate that\n             consent by signing and dating the informed consent document in the presence of study\n             personnel\n\n          -  Be suitable for receiving treatment with abiraterone acetate and prednisone\n\n          -  Patients must have histologically or cytologically confirmed adenocarcinoma of the\n             prostate without neuroendocrine differentiation or small cell histology\n\n          -  Patients may not receive any other investigational agent or dose escalation of\n             abiraterone acetate during study participation\n\n          -  Patient consents to comply to treatment with abiraterone acetate as directed by their\n             physician\n\n        Exclusion Criteria:\n\n          -  Taking a dose of abiraterone acetate other than 1g daily or lack of compliance to\n             daily dosing of abiraterone acetate and prednisone\n\n          -  Patients receiving spironolactone or any other steroidogenic compounds in excess of\n             the associated prednisone 5mg bid are excluded due to the potential for androgen\n             receptor agonism"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients receiving Abiraterone Acetate for Castrate Resistant Prostate Cancer"
            }
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 19, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01857908", 
            "org_study_id": "ABI Correlative Study", 
            "secondary_id": "12-5042-CE"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Adenocarcinoma", 
            "Abiraterone", 
            "Abiraterone Acetate", 
            "Zytiga", 
            "Correlative study", 
            "Castrate Resistant Prostate Cancer", 
            "Abiraterone Correlative study"
        ], 
        "lastchanged_date": "May 15, 2013", 
        "location": [
            {
                "contact": {
                    "last_name": "Bernie Eigl, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Vancouver", 
                        "country": "Canada", 
                        "state": "British Columbia", 
                        "zip": "V5Z 4E6"
                    }, 
                    "name": "BC Cancer Agency"
                }, 
                "investigator": [
                    {
                        "last_name": "Kim Chi, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Emma Guns, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Hans Adomat", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toronto", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "M5G2M9"
                    }, 
                    "name": "Princess Margaret Cancer Centre"
                }, 
                "status": "Active, not recruiting"
            }
        ], 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_groups": "1", 
        "overall_contact": {
            "email": "anthony.joshua@uhn.ca", 
            "last_name": "Anthony Joshua"
        }, 
        "overall_official": [
            {
                "affiliation": "Princess Margaret Cancer Centre", 
                "last_name": "Anthony Joshua, BSc(Med) MBBS PhD FRACP", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "British Columbia Cancer Agency", 
                "last_name": "Bernie Eigl, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Canada: Ethics Review Committee"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "PSA nadir samples will be assessed and compared to pre-Abiraterone treatment samples post completion of study", 
            "measure": "PSA", 
            "safety_issue": "No", 
            "time_frame": "Patients will be followed from Day 1 (date of initiation of Abiraterone treatment) until the date of first documented progression (estimated to be 1 year). PSA will be assessed every 30 days (approximately) until the time of PSA/clinical progression"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01857908"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "University Health Network, Toronto", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University Health Network, Toronto", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2012", 
        "study_design": "Observational Model: Case Control, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "April 2013"
    }
}